Key transaction details
Adaptive Biotechnologies Corp (NASDAQ: ADPT) President and Chief Operating Officer Julie Rubinstein completed a set of equity transactions between April 14 and April 16, 2026. Over that three-day span Rubinstein sold a total of 57,180 shares of common stock for approximately $826,251, with sale prices ranging from $14.18 to $14.61 per share. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan that Rubinstein adopted on November 18, 2025.
On the same dates, Rubinstein exercised stock options to acquire 44,166 shares of Adaptive Biotechnologies common stock at an exercise price of $8.46 per share, representing a total outlay of $373,644. After completing the sales and the option exercises, Rubinstein directly holds 408,160 shares of the company.
Company performance and valuation snapshot
Adaptive’s shares have delivered an 88% return over the past year. Despite this run-up, InvestingPro analysis indicates the company appears overvalued versus its Fair Value assessment at current price levels.
Quarterly results and analyst reactions
Adaptive reported fourth-quarter 2025 results that beat expectations. The company posted earnings per share of -$0.09 versus a consensus forecast of -$0.18, a 50% positive surprise relative to analysts' estimates. Revenue for the quarter reached $71.7 million, exceeding the expected $59.33 million by 20.85%.
Following those results and the company’s guidance, several research firms updated their views. BTIG raised its price target to $22 from $21 while keeping a Buy rating, citing strength in the firm’s Minimal Residual Disease, or MRD, business. That MRD segment delivered 54% year-over-year growth in the fourth quarter of 2025 and 46% year-over-year revenue expansion for the full fiscal year. TD Cowen raised its price target to $21 after the company’s pre-announced fourth-quarter results and guidance. Piper Sandler reiterated an Overweight rating, pointing to Adaptive’s position in the MRD market.
Context for investors
The insider sales were executed under a pre-established 10b5-1 plan, and the concurrent option exercises reduced Rubinstein’s net cost for acquiring additional shares. The company’s recent operating results and the analysts’ adjustments reflect revenue momentum in its MRD business, while InvestingPro’s Fair Value assessment suggests questions about current valuation relative to fundamentals.
Investors seeking additional valuation detail and a broader view of executive trading patterns can consult the Pro Research Report available through InvestingPro, which covers this company and more than 1,400 other U.S. equities.